Radioligand Therapy Trends and Forecast
The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Radioligand Therapy by Segment
The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.
Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:
• Fluorine – 18
• Gallium - 68
• Lutetium - 177
• Others
Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:
• Prostate-Specific Membrane Antigen
• Somatostatin Receptor
• Epidermal Growth Factor Receptor
• Others
Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
• Prostate Cancer
• Neuroendocrine Tumors
• Breast Cancer
• Others
Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals & Clinics
• Diagnostic Centers
• Others
Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Radioligand Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-
• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma
Radioligand Therapy Market Insights
Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.
North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Features of the Global Radioligand Therapy Market
Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).
Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the radioligand therapy market size?
Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.
Q2. What is the growth forecast for radioligand therapy market?
Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the radioligand therapy market?
Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.
Q4. What are the major segments for radioligand therapy market?
Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.
Q5. Who are the key radioligand therapy market companies?
Answer: Some of the key radioligand therapy companies are as follows:
• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma
Q6. Which radioligand therapy market segment will be the largest in future?
Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine – 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Radioligand Therapy Market, Radioligand Therapy Market Size, Radioligand Therapy Market Growth, Radioligand Therapy Market Analysis, Radioligand Therapy Market Report, Radioligand Therapy Market Share, Radioligand Therapy Market Trends, Radioligand Therapy Market Forecast, Radioligand Therapy Companies, write Lucintel analyst at email:
helpdesk@lucintel.com. We will be glad to get back to you soon.